MRNA Moderna PE ratio, current and historical analysis
The current PE ratio of MRNA can't be determined, as the TTM EPS of -$9.28 is negative. The last recorded PE ratio for Moderna was 39.19 in June 2023.
MRNA PE ratio history
The average historical PE ratio of Moderna for the last four years is 22.07. Over the past four years, MRNA's PE ratio was at its highest in the Mar 2021 quarter at 90.31, when the stock price was $130.95 and the EPS was $1.45. The lowest value was in the Sep 2022 quarter, when it reached 4.03 with a price of $118.25 and an EPS of $29.37.
Moderna PE ratio by year
Maximum annual increase: 0.84% in 2022
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $41.58 | -$9.28 |
| 2023 | N/A | N/A | $99.45 | -$12.33 |
| 2022 | 8.45 | 0.84% | $179.62 | $21.26 |
| 2021 | 8.38 | N/A | $253.98 | $30.31 |
| 2020 | N/A | N/A | $104.47 | -$1.96 |
| 2019 | N/A | N/A | $19.56 | -$1.55 |
| 2018 | N/A | N/A | $15.27 | -$4.95 |
| 2017 | N/A | N/A | N/A | -$4.18 |
| 2016 | N/A | N/A | N/A | -$3.79 |
Moderna PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | N/A | N/A | $41.58 | -$9.28 |
| Sep 2024 | N/A | N/A | $66.83 | -$5.81 |
| Jun 2024 | N/A | N/A | $118.75 | -$15.37 |
| Mar 2024 | N/A | N/A | $106.56 | -$15.66 |
| Dec 2023 | N/A | N/A | $99.45 | -$12.33 |
| Sep 2023 | N/A | N/A | $103.29 | -$9.1 |
| Jun 2023 | 39.19 | 213.02% | $121.5 | $3.1 |
| Mar 2023 | 12.52 | 48.17% | $153.58 | $12.27 |
| Dec 2022 | 8.45 | 109.68% | $179.62 | $21.26 |
| Sep 2022 | 4.03 | -1.23% | $118.25 | $29.37 |
| Jun 2022 | 4.08 | -13.92% | $142.85 | $34.97 |
| Mar 2022 | 4.74 | -43.44% | $172.26 | $36.35 |
| Dec 2021 | 8.38 | -61.79% | $253.98 | $30.31 |
| Sep 2021 | 21.93 | -18.9% | $384.86 | $17.55 |
| Jun 2021 | 27.04 | -70.06% | $234.98 | $8.69 |
MRNA average PE ratio chart
MRNA PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| MRK Merck & Co Inc | 13.77 | $235.2B |
| NVS Novartis AG | 18.94 | $221.47B |
| JNJ Johnson & Johnson | 28.02 | $393.96B |
| RGLS Regulus Therapeutics Inc | N/A | $90.75M |
| ARWR Arrowhead Pharmaceuticals Inc | N/A | $1.87B |
| ALNY Alnylam Pharmaceuticals Inc | N/A | $36.68B |
| MRNA Moderna Inc | N/A | $12.6B |
Frequently asked questions
What is Moderna's PE ratio?
The current price to earnings ratio of MRNA can't be calculated, as its EPS of -$9.28 is negative.
What is the 3-year average PE ratio for Moderna (MRNA)?
The 3-year average PE ratio for MRNA stock is 12.17.
What is the 5-year average PE ratio for Moderna (MRNA)?
The 5-year average PE ratio for MRNA stock is 22.07.
What is the highest PE ratio for MRNA?
In the last four years, the Mar 2021 quarter recorded the highest quarterly PE ratio at 90.31.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.